Headlines

Incyte (INCY) announces positive topline results from pivotal study of Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma

Newsquawk Staff ·

Incyte (INCY) announces positive topline results from pivotal study of Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma.

Related headlines